FDA panel backs Pfizer drug for kidney cancer
Wednesday, December 7, 2011 - 13:30
in Health & Medicine
(AP) -- A panel of advisers to the Food and Drug Administration voted Wednesday that the benefits of a Pfizer kidney cancer drug outweigh its risks, according to a company spokeswoman.